CD164L2

Across TCGA pan-cancer cohorts, CD164L2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD164L2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD164L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD164L2 expression acts as an unfavorable survival marker.

LUAD, BLCA, and MESO are the cancer types where CD164L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
BLCA	DFS	Median	All	0.100	0.626	<.001	18	view →
MESO	DFS	Median	All	0.098	0.366	.039	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD164L2–LUAD (OS)

Open the LUAD breakdown →